No Data
No Data
Novo Nordisk's Ozempic Gets FDA Approval for Kidney Disease
Jonathan Wolleben's Positive Outlook on Structure Therapeutics, Inc. Driven by Unique Small Molecule Amylin Agonist and Promising Obesity Pipeline
We're Not Very Worried About Structure Therapeutics' (NASDAQ:GPCR) Cash Burn Rate
Allurion Stock Soars 70% on Weight-loss Therapy Update
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $50